Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway.
Jer-Wei ChangWen-Hung KuoChiao-Mei LinWen-Ling ChenShih-Hsuan ChanMeng-Fan ChiuI-Shou ChangShih-Sheng JiangFang-Yu TsaiChung-Hsing ChenPei-Hsin HuangKing-Jen ChangKai-Ti LinSheng-Chieh LinMing-Yang WangYih-Huei UenChi-Wen TuMing-Feng HouShih-Feng TsaiChen-Yang ShenShiao-Lin TungLu-Hai WangPublished in: Oncogene (2018)
The early onset breast cancer patients (age ≤ 40) often display higher incidence of axillary lymph node metastasis, and poorer five-year survival than the late-onset patients. To identify the genes and molecules associated with poor prognosis of early onset breast cancer, we examined gene expression profiles from paired breast normal/tumor tissues, and coupled with Gene Ontology and public data base analysis. Our data showed that the expression of GAS7b gene was lower in the early onset breast cancer patients as compared to the elder patients. We found that GAS7 was associated with CYFIP1 and WAVE2 complex to suppress breast cancer metastasis via blocking CYFIP1 and Rac1 protein interaction, actin polymerization, and β1-integrin/FAK/Src signaling. We further demonstrated that p53 directly regulated GAS7 gene expression, which was inversely correlated with p53 mutations in breast cancer specimens. Our study uncover a novel regulatory mechanism of p53 in early onset breast cancer progression through GAS7-CYFIP1-mediated signaling pathways.
Keyphrases
- early onset
- late onset
- poor prognosis
- gene expression
- signaling pathway
- genome wide
- end stage renal disease
- room temperature
- lymph node metastasis
- genome wide identification
- ejection fraction
- long non coding rna
- copy number
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- prognostic factors
- carbon dioxide
- transcription factor
- lymph node
- peritoneal dialysis
- wild type
- emergency department
- cell migration
- early stage
- machine learning
- mental health
- pi k akt
- neoadjuvant chemotherapy
- small molecule
- genome wide analysis
- patient reported outcomes
- tyrosine kinase
- epithelial mesenchymal transition
- young adults
- locally advanced
- adverse drug